Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

MEI Pharma, Inc. - Common Stock (NQ: MEIP )

2.739 +0.019 (+0.71%)
Streaming Delayed Price Updated: 3:30 PM EST, Jan 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about MEI Pharma, Inc. - Common Stock

< Previous 1 2 3 4 Next >
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma to Release 2022 Fiscal Year End Financial Results and Provide Corporate Update on September 8, 2022
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma and Kyowa Kirin Announce Publication in The Lancet Oncology of Data from Phase 1b Clinical Study of Zandelisib in Patients with Relapsed or Refractory B-cell Malignancy
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Appoints Human Resources Executive Anne Frese as Chief People Officer
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma and Kyowa Kirin Report Clinical Data on Zandelisib at European Hematology Association 2022 Hybrid Congress
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma and Kyowa Kirin Announce Acceptance of Abstract for Presentation at the American Society of Clinical Oncology Annual Meeting 2022
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Reports Third Quarter Fiscal Year 2022 Results and Operational Highlights
From MEI Pharma, Inc.
Via Business Wire
MEI ALERT: Bragar Eagel & Squire, P.C. is Investigating MEI Pharma, Inc. on Behalf of MEI Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
MEI PHARMA ALERT: Bragar Eagel & Squire, P.C. is Investigating MEI Pharma, Inc. on Behalf of MEI Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of MEI Pharma, Inc. (MEIP) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of MEI Pharma, Inc. (MEIP) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in MEI Pharma, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
MEI Pharma to Present at the H.C. Wainwright Global Investment Conference 2022
From MEI Pharma, Inc.
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of MEI Pharma, Inc. (MEIP) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in MEI Pharma, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Rosen Law Firm Encourages MEI Pharma, Inc. Investors with Losses to Inquire About Class Action Investigation – MEIP
From Rosen Law Firm
Via Business Wire
MEI Pharma and Kyowa Kirin Announce Acceptance of Two Abstracts for Presentation at the European Hematology Association 2022 Hybrid Congress
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Announces Two Presentations at the American Association for Cancer Research Annual Meeting 2022
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma and Kyowa Kirin Provide Regulatory Update on Zandelisib Following Meeting with the FDA
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Reports Second Quarter Fiscal Year 2022 Results and Operational Highlights
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Strengthens Clinical and Quality Expertise with New Key Executive Appointments
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From MEI Pharma, Inc.
Via Business Wire
MEI Pharma Announces Closing of Public Offering of Common Stock
From MEI Pharma, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.